BioSpace News Archive

Johnson & Johnson and Emergent BioSolutions are accusing each other of breaching their COVID-19 vaccine supply agreement.

BioSpace caught up with Tara Frenkl and Nelson Ambrogio ahead of ASCO to discuss Bayer’s goal of becoming a top 10 oncology company by 2030.

The Phase III ADvocate 1 and 2 studies on lebrikizumab showed that eight out of 10 patients with atopic dermatitis maintained skin clearance in the 12 months they had been under treatment.

Novartis has fallen victim to a cyberattack. The Swiss pharma giant’s data was hijacked by a well-known online extortion ring dubbed Industrial Spy.

Seres Therapeutics, Inc. announced that the company’s Phase III Ecospor IV study demonstrated a strong safety profile in addition to statistically significant positive results against C. difficile infection.

Code Bio, a biotechnology company leading the way in targeted non-viral delivery of generic medicines, closed a $75 million Series A financing round on Tuesday.

scPharmaceuticals Inc. announced that the Company has had two abstracts accepted for presentation at the American Association of Heart Failure Nurses 18th Annual Meeting, which is being held June 15-18 in Orlando, Florida.

Enlivex Therapeutics Ltd. announced that company management will present a corporate update at the 2022 Jefferies Healthcare Conference, which is taking place at the Marriott Marquis in New York, NY.

eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a biopharmaceutical company pioneering the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that the Company will present and host 1x1 meetings at JMP Securities Life Sciences Conference.

AUM Biosciences, a global clinical-stage biotech company, focused on discovering and developing precision oncology therapeutics, today announced that it has received authorization from the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for the clinical trial evaluating AUM001, a selective translation inhibitor.